Squarepoint Ops LLC Purchases 98,489 Shares of Surmodics, Inc. (NASDAQ:SRDX)

Squarepoint Ops LLC grew its stake in shares of Surmodics, Inc. (NASDAQ:SRDX - Free Report) by 154.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 162,066 shares of the company's stock after acquiring an additional 98,489 shares during the quarter. Squarepoint Ops LLC owned about 1.13% of Surmodics worth $6,418,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Barclays PLC boosted its holdings in shares of Surmodics by 16.0% during the 3rd quarter. Barclays PLC now owns 88,750 shares of the company's stock valued at $3,443,000 after acquiring an additional 12,271 shares during the last quarter. SG Americas Securities LLC boosted its holdings in shares of Surmodics by 22.1% during the 4th quarter. SG Americas Securities LLC now owns 6,940 shares of the company's stock valued at $275,000 after acquiring an additional 1,255 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its holdings in shares of Surmodics by 165.3% during the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 30,000 shares of the company's stock valued at $1,188,000 after acquiring an additional 18,692 shares during the last quarter. Gardner Lewis Asset Management L P boosted its holdings in shares of Surmodics by 23.5% during the 4th quarter. Gardner Lewis Asset Management L P now owns 262,878 shares of the company's stock valued at $10,410,000 after acquiring an additional 49,944 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its holdings in shares of Surmodics by 40.9% during the 4th quarter. Wells Fargo & Company MN now owns 7,032 shares of the company's stock valued at $278,000 after acquiring an additional 2,041 shares during the last quarter. Hedge funds and other institutional investors own 96.63% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on SRDX. Wall Street Zen began coverage on shares of Surmodics in a report on Monday, February 3rd. They issued a "hold" rating on the stock. Lake Street Capital raised shares of Surmodics from a "hold" rating to a "buy" rating and set a $43.00 price objective on the stock in a report on Friday, March 7th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Surmodics in a report on Wednesday, April 30th.

Surmodics Stock Performance

Shares of SRDX traded down $0.31 on Friday, reaching $29.22. The company's stock had a trading volume of 4,014 shares, compared to its average volume of 266,383. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.45 and a quick ratio of 4.29. The stock has a market capitalization of $417.82 million, a P/E ratio of -28.93 and a beta of 1.32. The stock's 50 day simple moving average is $28.75 and its two-hundred day simple moving average is $33.63. Surmodics, Inc. has a 12-month low of $26.00 and a 12-month high of $42.44.

Surmodics (NASDAQ:SRDX - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.07). The business had revenue of $28.09 million during the quarter, compared to analysts' expectations of $32.23 million. Surmodics had a negative return on equity of 4.39% and a negative net margin of 11.48%. Research analysts forecast that Surmodics, Inc. will post 0.2 earnings per share for the current fiscal year.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).